Ayala Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients with rare tumors and aggressive cancers. Its efforts center on assets like aspacytarabine (BST-236), a proprietary anti-metabolite designed for first-line treatment in unfit acute myeloid leukemia patients, addressing a critical need in hematologic malignancies. Previously, the company advanced AL102, an oral gamma secretase inhibitor targeted at desmoid tumors—a rare connective tissue cancer—in the Phase 2/3 RINGSIDE study, and AL101 for recurrent or metastatic adenoid cystic carcinoma. Ayala Pharmaceuticals Inc. has also developed Listeria monocytogenes-based immunotherapies, including programs for lung cancer, prostate cancer, and other solid tumors, leveraging a proprietary platform to stimulate T-cell responses against tumor antigens. These initiatives position the company within the oncology drug development sector, emphasizing precision therapies for hard-to-treat indications. Headquartered in Wilmington, Delaware, with operations linked to Monmouth Junction, New Jersey, Ayala Pharmaceuticals Inc. operates in the pharmaceutical preparation manufacturing industry, contributing to advancements in targeted cancer treatments.